Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorder) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy – Drugs In Development, 2021, provides an overview of the Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 2 and 3 respectively.

Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (Metabolic Disorders).

– The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Proliferative Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Aerie Pharmaceuticals Inc

Antisense Therapeutics Ltd

Apexian Pharmaceuticals Inc

Boehringer Ingelheim International GmbH

Generium

Kubota Vision Inc

Kuur Therapeutics Ltd

Oxurion NV

Ribomic Inc

Samsung Bioepis Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Proliferative Diabetic Retinopathy (PDR) - Overview

Proliferative Diabetic Retinopathy (PDR) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development

Aerie Pharmaceuticals Inc

Antisense Therapeutics Ltd

Apexian Pharmaceuticals Inc

Boehringer Ingelheim International GmbH

Generium

Kubota Vision Inc

Kuur Therapeutics Ltd

Oxurion NV

Ribomic Inc

Samsung Bioepis Co Ltd

Proliferative Diabetic Retinopathy (PDR) - Drug Profiles

APX-3330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-13503 SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atesidorsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-764524 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brolucizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emixustat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-687 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proliferative Diabetic Retinopathy (PDR) - Dormant Projects

Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones

Featured News & Press Releases

May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Aerie Pharmaceuticals Inc, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Antisense Therapeutics Ltd, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Apexian Pharmaceuticals Inc, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Boehringer Ingelheim International GmbH, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Generium, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Kubota Vision Inc, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Kuur Therapeutics Ltd, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Oxurion NV, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Ribomic Inc, 2021

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Samsung Bioepis Co Ltd, 2021

Proliferative Diabetic Retinopathy (PDR) – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports